SMART quality & compliance
Brexit and its impact on Pharma Compliance
The definite impact of Brexit on the Pharma Industry is, for the moment, vague. What is clear though, is that Brexit will have a big impact on the pharma supply chain and pharma compliance bodies. Due to Brexit the EMA must move to a new location, which is Amsterdam. All pharma compliance bodies which need to sit in an EU-country need to also move e.g.: QP, QPPV, Regulatory Affairs, etc. One advantage is, that after Brexit, the MHRA is only allowed to do inspections for medicines sold on the UK market like the FDA. It will be a long process…
Read More >